Metacrine, Inc. (MTCR)
| Market Cap | 19.64M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -60.32M |
| Shares Out | 42.47M |
| EPS (ttm) | -1.93 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 675,051 |
| Open | 0.470 |
| Previous Close | 0.470 |
| Day's Range | 0.460 - 0.488 |
| 52-Week Range | 0.350 - 4.120 |
| Beta | n/a |
| Analysts | Sell |
| Price Target | 1.02 (+120.5%) |
| Earnings Date | Aug 11, 2022 |
About MTCR
Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California. [Read more...]
Financial Performance
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for MTCR stock is "Sell." The 12-month stock price forecast is 1.02, which is an increase of 120.54% from the latest price.
News
Metacrine Reports First-Quarter 2022 Results
SAN DIEGO, May 12, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal diseases, tod...
Metacrine Reports Fourth-Quarter 2021 Results
SAN DIEGO, March 30, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal diseases, t...
Metacrine Announces Executive Leadership Changes
SAN DIEGO, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal diseases, to...
Metacrine To Slash Its Workforce By 50%
Metacrine Inc (NASDAQ: MTCR) will ax half of its staff to conserve cash as it makes a last-stand drug development effort. Its shares are mired deep in penny stock territory after it floated its IPO in 2...
Metacrine Updates IBD Clinical Development Strategy and Implements Restructuring Plan
SAN DIEGO, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal and liver di...
Metacrine Announces Resignation of Chief Medical Officer
SAN DIEGO, Dec. 27, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal and liver di...
Is the Options Market Predicting a Spike in Metacrine (MTCR) Stock?
Investors need to pay close attention to Metacrine (MTCR) stock based on the movements in the options market lately.
3 Penny Stocks To Watch After Jerome Powell's Fed Announcement
3 penny stocks to watch after Fed Chair Powells press conference. The post 3 Penny Stocks To Watch After Jerome Powell's Fed Announcement appeared first on Penny Stocks to Buy, Picks, News and Informati...
Metacrine Reports Third-Quarter 2021 Results
SAN DIEGO, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal and liver di...
Metacrine Reports Interim Results for MET642 Phase 2a Trial in Patients with NASH and Announces a Strategic Re-Priori...
SAN DIEGO, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal di...
Metacrine Achieves Full Enrollment for MET642 Phase 2a Trial in Patients With Nash
SAN DIEGO, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal d...
Metacrine to Host Virtual R&D Day for Analysts and Investors on September 15, 2021
SAN DIEGO, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal d...
Metacrine to Present at H.C. Wainwright 23rd Annual Global Investment Conference
SAN DIEGO, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal d...
Metacrine Updates MET642 Clinical Development Milestone and Reports Second-Quarter 2021 Results
SAN DIEGO, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal di...
Metacrine to Present at 2021 Canaccord Genuity Growth Conference
SAN DIEGO, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal di...
Metacrine to Present New Preclinical Data in Inflammatory Bowel Disease (IBD) at European Crohn's and Colitis Organis...
SAN DIEGO, July 06, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal di...
Metacrine and Its Partners to Present Data at the EASL International Liver Congress™ 2021
SAN DIEGO, June 17, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal di...
Metacrine Achieves Full Enrollment for MET409 Phase 2a Combination Trial in Patients With Type 2 Diabetes and NASH
SAN DIEGO, June 02, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal di...
Metacrine to Present at 2021 Jefferies Healthcare Conference
SAN DIEGO, May 26, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal dis...
Metacrine to Present New Preclinical Data on MET642 in Inflammatory Bowel Disease at Digestive Disease Week 2021 Virt...
Preclinical data demonstrate synergistic effects between FXR agonist and JAK inhibitor, suggesting the potential for a change in the treatment paradigm for IBD Preclinical data demonstrate synergistic e...
Metacrine Achieves Enrollment Target for MET642 Phase 2a Trial Interim Analysis
SAN DIEGO, May 18, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal dis...
Metacrine to Present at 2021 RBC Global Healthcare Conference
SAN DIEGO, May 11, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal dis...
Metacrine Appoints Dr. Julia C. Owens to Its Board of Directors
SAN DIEGO, April 05, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal d...
Metacrine Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results
Interim Data from the Phase 2a Trial of MET642 in NASH Patients On-Track to be Reported in the Fourth Quarter of 2021
Metacrine to Present Final Results from Phase 1 Trial of MET642, an Optimized FXR Agonist, at the 2021 NASH-TAG Confe...
Sustained pharmacodynamic effects with once-daily oral dosing, without increases in LDL cholesterol or pruritus at any dose level in healthy volunteers Sustained pharmacodynamic effects with once-daily ...